Jun 14, 2023 / 11:40PM GMT
Andrea R. Tan - Goldman Sachs Group, Inc., Research Division - Research Analyst
Thanks, everyone, for joining us for the last session of the third day of our conference. I'm pleased to be joined by Victor Perlroth, CEO of Kodiak Sciences. Thank you so much, Victor.
Victor Perlroth - Kodiak Sciences Inc. - Co-Founder, Chairman, CEO & President
Thanks a lot, Andrea. Can you hear me?
Questions and Answers:
Andrea R. Tan - Goldman Sachs Group, Inc., Research Division - Research AnalystYes. So maybe we can start. We're at an exciting time for Kodiak. We're sitting in front of 4 Phase III trials that are coming, starting in July. Maybe help frame -- maybe let's take a step back actually. Let's talk about your antibody platform, and how is it uniquely positioned to address this idea of durability?
Victor Perlroth - Kodiak Sciences Inc. - Co-Founder, Chairman, CEO & President
Right. Well, that's a good question because we start with the science of the design and then